Navigation Links
New Chromatography Detectors From Varian, Inc. Extend the Range of Universal Detection for HPLC and LC/MS
Date:3/3/2008

PALO ALTO, Calif., March 3 /PRNewswire-FirstCall/ -- Varian, Inc. (NasdaqGS: VARI) announced today the release of two new evaporative light scattering detectors (ELSD) for conventional and high speed liquid chromatography. With their universal response, full gradient and solvent compatibility, and excellent baseline stability, Varian ELSDs possess key advantages over conventional UV and RI detectors for busy pharmaceutical and analytical laboratories. In addition, they complement electrospray detection in LC/MS (Liquid Chromatography/Mass Spectrometry) for compounds that are difficult to ionize.

With the capability to deliver sub-ambient evaporation down to 10 degrees Celsius, the new Varian 385-LC provides maximum sensitivity for compounds with significant volatility below 30 degrees Celsius, giving it the widest application range of all ELSDs. The new Varian 380-LC is the instrument of choice for non-volatile compounds, including analyses where elevated temperature offers higher sensitivity.

Both instruments offer unrivalled flexibility and sensitivity, delivering a universal response down to the low nanogram range for trace analysis. Real time gas management eliminates solvent effects for constant response across a gradient. Digital data collection enables the detectors to be interfaced with multi-vendor analysis platforms and removes the need for analog to digital interfaces. The new instruments allow chromatographers to save time and improve productivity with on-the-fly adjustment of light source intensity for sample mixtures with a wide concentration range. Excellent reproducibility (plus or minus < 2%), greatly enhances productivity. Fast data output rates and extremely low dispersion are ideal for high speed LC, an increasingly important analytical technique.

"These programmable ELSDs provide chemists with unrivalled control of an analysis in real time," says Martin O'Donoghue, Senior Vice President, Scientific Instruments, Varian, Inc. "Varian's new 380-LC family of detectors bring sensitive and accurate detection capability to an even wider range of applications."

Varian, Inc. is a leading worldwide supplier of scientific instruments and vacuum technologies for life science and industrial applications. The company provides complete solutions, including instruments, vacuum products, laboratory consumable supplies, software, training and support through its global distribution and support systems. Varian, Inc. employs approximately 3,900 people worldwide and operates manufacturing facilities in North America, Europe and Asia Pacific. Varian, Inc. had fiscal year 2007 sales of $921 million, and its common stock is traded on the NASDAQ Global Select Market under the symbol, "VARI." Further information is available on the company's Web site: http://www.varianinc.com.

For more technical information about Varian's Scientific Instruments, please visit http://www.varianinc.com

For More Information, Contact:

Public Relations

Varian, Inc.

650.424.3845

pr@varianinc.com


'/>"/>
SOURCE Varian, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Thermo Fisher Scientific Acquires Leading Chromatography Consumables Provider, La-Pha-Pack
2. Varian, Inc. Reports First Quarter 2008 Results
3. Roche Extends Tender Offer for Ventana
4. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
5. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
6. Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission
7. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
8. ChemAxon and Agilent Technologies Sign Agreement Extending JChem Integration With Kalabie Electronic Lab Notebook
9. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
10. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
11. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... India , Jan. 19, 2017  Market Research Future has ... Global Market for Liquid Biopsy is growing rapidly and expected to ... Market Highlights ... The Global Liquid Biopsy Market has been assessed as a ... growth figures and boom in the coming future. There has been ...
(Date:1/19/2017)... , Jan 19, 2017 Research and Markets ... has announced the addition of ... Material, Application - Forecast to 2025" report to their ... The report provides a detailed analysis on current and ... forecasts till 2025, using estimated market values as the base numbers ...
(Date:1/19/2017)... and GAITHERSBURG, Md. , Jan. ... and Altimmune, Inc., a privately-held immunotherapeutics company targeting ... definitive agreement for the merger of PharmAthene and ... include Novartis Venture Fund, HealthCap, Truffle Capital and ... fully-integrated and diversified immunotherapeutics company with four clinical ...
(Date:1/19/2017)... ... January 18, 2017 , ... The ... (NIH) to update its Data Sharing Policy. Specifically, the nation’s leading informatics experts, ... subject to the existing policy. AMIA recommended that NIH earmark funding for researchers ...
Breaking Biology Technology:
(Date:1/18/2017)... , Jan. 18, 2017 ... company that supports the entire spectrum of clinical ... been another record-breaking year for the organization in ... interest in MedNet,s eClinical products and services. The ... tremendous marketplace success of iMedNet ...
(Date:1/12/2017)... NEW YORK , Jan. 12, 2017  New research ... around the office of the future.  1,000 participants were simply ... last three months which we may consider standard issue.  Insights ... office of 2017 were also gathered from futurists and industry ... and Dr. James Canton .  Some ...
(Date:1/11/2017)... NEW BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, ... from Foundation Venture Capital Group, Inc., has been named to the ... Johnson, 27,  was one of 600 people in 20 fields ... only four percent of the 15,000 applicants were selected. ... He is currently a PhD ...
Breaking Biology News(10 mins):